Characteristics and Prognostic Outcomes of Diaphragmatic Ultrasound in Myasthenia Gravis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06707727

Enrollment

100

Registered

2024-11-27

Start date

2024-07-01

Completion date

2026-06-30

Last updated

2024-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myasthaenia Gravis

Brief summary

The goal of this observational study is to learn about the characteristics and prognostic outcomes of diaphragmatic ultrasound in myasthenia gravis. The main question it aims to answer is: Does diaphragmatic ultrasound predict prognosis of myasthenia gravis in six months? Participants diagnosed as myasthenia gravis will take the diaphragm ultrasound examinations.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

* 1: Patients who seek treatment at the First Affiliated Hospital of Chongqing Medical University and have fluctuating skeletal muscle weakness and at least one of the following three conditions will be included: positive reaction to cholinesterase inhibitors 2: Serum positive antibodies against acetylcholine receptors, muscle specific kinases, or lipoprotein related proteins 3: Repeated electrical stimulation examination showed a decrease in wave amplitude.

Exclusion criteria

* 1: Patients with lung disease or heart failure, or a history of non-invasive ventilator or tracheotomy

Design outcomes

Primary

Measure	Time frame
QMG changes	6 months

Secondary

Measure	Time frame	Description
Changes in medication type or dose	6 months	acetylcholinesterase inhibitors, glucocorticoid, immunosuppressant
respiratory infection	6 months	—

Countries

China

Outcome results